Published in
Taylor & Francis, Expert Opinion on Investigational Drugs, 8(27), p. 649-660
DOI: 10.1080/13543784.2018.1506764
Links
Tools
Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn’s disease
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 